Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.
Subscribe to our weekly newsletter for the latest in industry news, expert insights, dedicated information security content and online events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback